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Forced swimming testa b s t r a c t
Depression is a common mental disorder that affects millions of individuals worldwide. Available
monoaminergic antidepressants are far from ideal since they show delayed onset of action and are inef-
fective in approximately 40% of patients, thus indicating the need of new and more effective drugs. ATP
signaling through P2 receptors seems to play an important role in neuropathological mechanisms
involved in depression, since their pharmacological or genetic inactivation induce antidepressant-like
effects in the forced swimming test (FST). However, the mechanisms involved in these effects are not
completely understood. The present work investigated monoamine involvement in the antidepressant-
like effect induced by non-specific P2 receptor antagonist (PPADS) administration. First, the effects of
combining sub-effective doses of PPADS with sub-effective doses of fluoxetine (FLX, selective serotonin
reuptake inhibitor) or reboxetine (RBX, selective noradrenaline reuptake inhibitor) were investigated
in mice submitted to FST. Significant antidepressant-like effect was observed when subeffective doses
of PPADS was combined with subeffective doses of either FLX or RBX, with no significant locomotor
changes. Next, the effects of depleting serotonin and noradrenaline levels, by means of PCPA (p-
Chlorophenylalanine) or DSP-4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine hydrochloride) pre-
treatment, respectively, was investigated. Both, PCPA and DSP-4 pretreatment partially attenuated
PPADS-induced effects in FST, without inducing relevant locomotor changes. Our results suggest that
the antidepressant-like effect of PPADS involves modulation of serotonin and noradrenaline levels in
the brain.
 2017 Elsevier B.V. All rights reserved.1. Introduction
World Health Organization (WHO) estimates 350 million of
individuals are affected by depression globally, and it predicts
depression will be the main cause of morbidity and loss of produc-
tivity among all health conditions by 2030 (World Health
Organization, 2016). The current antidepressant drug therapy,
based on increasing monoamines availability (Elhwuegi, 2004), is
only effective in approximately 60% of the patients, and it takes3–4 weeks to be clinically effective (Blier, 2003; Racagni and
Popoli, 2008).
Great attention has been paid to the purinergic signaling in neu-
ropathological disorders such as Alzheimer and Parkinson disease,
anxiety, schizophrenia, drug addiction, and, of importance to the
present work, depression, (Abbracchio et al., 2009; Burnstock,
2008). Purinergic neurotransmission emerged from the work of
Prof. Burnstock describing adenosine 5’-triphosphate (ATP) as
non-adrenergic, non-cholinergic inhibitory transmitter in the
guinea-pigs (Abbracchio and Burnstock, 1994; Burnstock, 1972;
Burnstock, 1976). Since then, ATP has been described as a cotrans-
mitter in noradrenergic (Sperlagh et al., 1998), gabaergic (Jo and
Role, 2002), glutamatergic (Mori et al., 2001) and cholinergic
(Richardson and Brown, 1987) synaptic terminals, but vesicles
containing exclusively ATP have also been reported (Pankratov
et al., 2006). ATP released in synaptic cleft can be degraded by
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which also acts as a ligand for purinergic receptors (Zimmermann,
2006).
Purinergic neurotransmission comprises receptors for adeno-
sine and ATP, respectively termed P1 and P2. Based on molecular
cloning and pharmacological differences, P2 receptors can be
divided into P2Y and P2X receptors (Abbracchio and Burnstock,
1994). P2Y are G-protein coupled receptors that modulate
inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) levels
from membrane phosphoinositide metabolism (Pfeilschifter,
1990; Burnstock, 2007), while P2X are ion channels permeable to
Na+, K+ and Ca2+ (Burnstock, 2007; Benham and Tsien, 1987;
Bean, 1992). Currently, 8 subtypes of metabotropic P2Y receptors
(P2Y1,2,4,6,11,12,13,14) and 7 subtypes of ionotropic P2X receptors
(P2X1-7) have been described (Burnstock, 2007). P2 receptors are
widely expressed in cerebral structures involved in emotional
behavior such as hippocampus, cerebral cortex, ventral tegmental
area and locus coeruleus (Norenberg and Illes, 2000), either in glial
or neuronal cell types (Burnstock, 2008).
It has been recently reported that pharmacological blockade of
P2 receptors induces antidepressant-like effects in preclinical
models (Pereira et al., 2013; Csolle et al., 2013). Selective P2X7
antagonist also induced antidepressant-like effect in the chronic
mild stress model (Iwata et al., 2016) and similar behavioral phe-
notype was also described in animals with genetic deletion of
P2X7 receptors (Boucher et al., 2011; Basso et al., 2009). Despite
evidences of an antidepressant-like effect induced by P2R antago-
nist treatment, the involvement of serotonergic and/or noradrener-
gic mechanisms has not yet been investigated. Monoamine and
purinergic interplay is plausible given the fact that activation of
P2R can modulate brain glutamate and NO levels (Florenzano
et al., 2008; Pereira et al., 2013), which are both able to control
serotonin synthesis, stability and release (Kuhn and Arthur,
1997; Fossier et al., 1999). In support of that, P2X7R knockout ani-
mals showed changes in cerebral levels of noradrenaline and sero-
tonin (Csolle et al., 2013). Furthermore, the antidepressant-like
effect of NOS inhibitors and NMDA antagonists (Diniz et al.,
2016) are dependent of serotonin levels in the brain (Harkin
et al., 2003; du Jardin et al., 2016; Ulak et al., 2010). Therefore,
since P2R signaling modulate glutamate and NO release in the
brain, which then affects monoamine levels, we hypothesized the
antidepressant-like effect of the non-specific P2R antagonist PPADS
would involve the modulation of brain serotonin and/or nora-
drenaline levels.
Therefore, the present aims were: 1. To investigate if the com-
bination of sub-effective doses of P2R antagonist with subeffective
doses of antidepressants of different pharmacological classes (sero-
tonin or noradrenaline reuptake inhibitors) would be able to
induce antidepressant-like effect in mice submitted to forced
swimming test; 2. To investigate if depleting serotonin or nora-
drenalin levels, by means of pharmacological pretreatment with
PCPA (tryptophan hydroxylase inhibitor; Koe and Weissman,
1966) or DSP4 (noradrenergic neurotoxin; Grzanna et al., 1989),
could attenuate or even block the behavioral effect of P2R antago-
nist in the FST. Altogether, these data could help understanding if
monoamines would be involved in the mechanisms underlining
the antidepressant-like effect induced by P2R blockade.Fig. 1. Dose-response curves for FLX, RBX and PPADS treatment on mice FST and
OFT. (A) PPADS (3, 6.25, 12.5), FLX (10, 20, 30), RBX (2.5, 5, 10) or vehicle (10 mL/kg)
were administered 30 min before FST (n = 6, 7, 7, 7, 7, 5, 5, 7, 10, 9, respectively).
Data are expressed as mean ± SEM of immobility time (s); *p < 0.05, **p < 0.01 from
control group. (B) PPADS (6.25 mg/kg, n = 6), FLX (20 mg/kg, n = 6), RBX (5 mg/kg,
n = 6) or VEH (n = 6) was administered 30 min before being submitted to OFT. Data
are expressed as Mean ± SEM of total quadrant traveled in the OFT.2. Results
2.1. Dose-response curves for FLX, RBX and PPADS treatment on mice
submitted to FST or OFT
One-way ANOVA indicates a significant effect of drug treatment
on immobility time in the FST [F9,60 = 3.453. p < 0.05]. Treatmentwith PPADS (6.25 mg/kg), FLX (20 mg/kg) and RBX (5 mg/kg) sig-
nificantly decreased immobility time on FST (Dunn’s post hoc test,
p < 0.05), as seen in Fig. 1A. Effective doses of PPADS (6.25 mg/kg),
FLX (20 mg/kg) and RBX (5 mg/kg) were not able to change loco-
motor behavior of animals tested on OFT (Fig. 1B – F3,20 = 1.715,
non-significant – NS).2.2. Add on effects of PPADS sub-effective dose to FLX or RBX sub-
effective doses on FST and OFT
Two-way ANOVA indicates a significant treatment effect of first
injection with FLX or RBX [F2,38 = 7.831; p < 0.01], of second injec-
tion with PPADS [F1,38 = 4.534; p < 0.05] and an interaction
between factors [F2,38 = 4.727; p < 0.05]. In column comparison,
combination of sub-effective doses of PPADS (3 mg/kg) and FLX
(10 mg/kg) decreased immobility time compared to VEH/VEH
(p < 0.05) and VEH/PPADS (p < 0.01), whereas combination of
sub-effective doses of PPADS and RBX (2.5 mg/kg) decreased
immobility time compared to VEH/VEH (p < 0.01), VEH/PPADS
(p < 0.001) and RBX/VEH (p < 0.05) groups (Fig. 2A –
F5,38 = 5.915). Combination of sub-effective doses of PPADS
(3 mg/kg) and FLX (10 mg/kg) or RBX (2.5 mg/kg) did not change
locomotor activity of animals on OFT (Fig. 2B – F2,14 = 0.6730, NS).
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Two-way ANOVA indicated a significant treatment effect of
PPADS [F1,27 = 8.64; p < 0.01] but not of PCPA [F1,27 = 0.25; NS], nei-
ther interaction between both factors [F1,27 = 2.115; NS]. In column
comparison, immobility time of group VEH/PPADS is observed
lower than VEH/VEH group [F3,27 = 3.631, p < 0.05 – Fig. 3A; Dunn’s
post hoc test]. Moreover, PCPA+VEH, as well as PCPA+PPADS com-
bination did not significantly differ from VEH+VEH group
(Fig. 3A; p > 0.05 vs control, Dunn’s post hoc test). This indicates
PCPA did not induce effect per se, but it attenuated PPADS-
induced effects. Two-way ANOVA show no locomotor changeFig. 2. Add on effects of PPADS sub-effective dose with FLX or RBX sub-effective
doses on FST and OFT. (A) Sub-effective dose of FLX (10 mg/kg) or RBX (2.5 mg/kg)
was carried out after PPADS sub-effective dose (3 mg/kg) administration, 30 min
before FST. Six groups were obtained: VEH + VEH (n = 9), FLX + VEH (n = 6), RBX
+ VEH (n = 6), VEH + PPADS (n = 8), FLX + PPADS (n = 8), RBX + PPADS (n = 7). Data
are expressed as mean ± SEM of immobility time (s); *p < 0.05, **p < 0.01 from
control group; #p < 0.05, ##p < 0.01, ###p < 0.001 from respective groups outlined.
(B) Sub-effective dose of FLX (10 mg/kg) or RBX (2.5 mg/kg) was carried after PPADS
sub-effective dose (3 mg/kg) administration, 30 min before OFT. Three groups were
obtained: VEH + VEH (n = 6), FLX + PPADS (n = 6), RBX + PPADS (n = 5). Data are
expressed as Mean ± SEM of total quadrant traveled in the OFT.
Fig. 3. Effect of 5-HT depletion on PPADS effects on FST and OFT behavior. (A) PCPA
(150 mg/kg) or VEH was administered once daily for 4 days. On the fourth day, the
last dose of PCPA or VEH infusion were done 30 min before the second treatment
with VEH or PPADS (6.25 mg/kg). Animals were submitted to the FST 30 min after
the second injection. Thus, four groups were obtained: VEH + VEH (n = 7), PCPA
+ VEH (n = 8), PCPA + PPADS (n = 8), VEH + PPADS (n = 8). Data are expressed as
mean ± SEM of immobility time (s). (B) The same treatment protocol was
established as described above, but animals were submitted to the OFT instead of
the FST. Four groups were obtained: VEH + VEH (n = 6), PCPA + VEH (n = 6), PCPA
+ PPADS (n = 5), VEH + PPADS (n = 6). Data are expressed as Mean ± SEM of total
quadrant traveled in the OFT. *p < 0.05 from control group.
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F1,19 = 1.316; NS; interaction: F1,19 = 0.466; NS – Fig. 3B).
2.4. Effect of NA depletion on PPADS effects on FST and OFT
Two-way ANOVA indicates a significant interaction between
DSP4 and PPADS [F1,31 = 8.624; p < 0.01], however no effect of the
isolated treatments [DSP4: F1,31 = 1.016; PPADS: F1,31 = 1.198, NS
for both]. In column comparison, both groups DSP4/VEH and
VEH/PPADS showed decreased immobility time on FST compared
to VEH/VEH group [F3,31 = 3.423, p < 0.05 – Fig. 4A]. In addition,
two-way ANOVA indicated a significant effect of DSP4
[F1,24 = 9.58; p < 0.005] but not of PPADS [F1,24 = 1.91; NS] or inter-
action between factors [F1,24 = 1.11; NS] on OFT. In column com-
parison, a significant effect of DSP4 infusion on OFT was
observed [Fig. 4B – F1,24 = 9.580; p < 0.01].
2.5. 5HT, NA and 5HIAA levels on PFC and HPC of PCPA and DSP4
treated animals
According to student’s t test there was a significant decrease of
NA (t8 = 2.451), 5HIAA (t8 = 2.491) and 5HT (t8 = 3.885) hippocam-
pal levels in DSP4 treated mice. No difference was observed with
DSP4 treatment in frontal cortex (NA t10 = 0.018; 5HIAA
t10 = 1.178 and 5HT t10 = 1.672). Student’s t test identified a reduc-
tion in NA (t7 = 2.488) frontal cortex levels from PCPA treatment
but no change was observed in 5HIAA (t6 = 1.100) and 5HT
(t7 = 1.096) levels. In hippocampus, 5HIAA (t7 = 2.647) levels were
significantly reduced by PCPA treatment, but no change was
observed in NA (t7 = 0.159) and 5HT (t7 = 0.490) levels. All data
are found in Table 1.Fig. 4. Effect of NA depletion on PPADS effects on FST and OFT. (A) DSP4 (20 mg) was
infused i.c.v. 24 h before FST. Injection of PPADS (6.25 mg/kg) was performed
30 min before FST. Four groups were obtained: VEH + VEH (n = 7), DSP4 + VEH
(n = 8), DSP4 + PPADS (n = 9), VEH + PPADS (n = 8). Data are expressed as mean ± -
SEM of immobility time (s). (B) The same treatment protocol was established as
described above, but animals were submitted to the OFT instead of the FST. Four
groups were obtained: VEH + VEH (n = 7), DSP4 + VEH (n = 7), DSP4 + PPADS (n = 7),
VEH + PPADS (n = 7). Data are expressed as Mean ± SEM of total quadrant traveled
in the OFT. *p < 0.05 from control group.3. Discussion
This work was designed to investigate the involvement of
monoamines in PPADS induced antidepressant-like effects in FST.
We found that: 1. Combination of subeffective doses of PPADS with
subeffective doses of serotonergic (FLX) or noradrenergic (RBX)
antidepressants induced significant effects in mice FST; 2. Pretreat-
ment with PCPA (serotonin synthesis inhibitor) or DSP-4 (nora-
drenergic toxin) decreased serotonin and noradrenaline levels in
the brain and attenuated PPADS induced antidepressant-like
effects. None of these effects were associated to locomotor changes
in the OFT.
Stressful events, a key factor for susceptibility to depression,
would be expected to affect behavior in the FST. In fact, immobility
time of rats exposed to swim session is increased after uncontrol-
lable stress and decreased by antidepressant treatment (Porsolt
et al., 1977; Cryan et al., 2002a; Nestler and Hyman, 2010). How-
ever, no consensus is established about what immobility in the
FST represents, whether it is a behavioral despair or a passive-
coping (Cryan et al., 2002a). Either way, the antidepressant efficacy
of decreasing immobility time confers to FST a presumable predic-
tive validity and allows the study of mechanism of action for puta-
tive new drugs. In this work, systemic treatment with P2R
antagonist reduced immobility time in the FST, further supporting
the modulation of the purinergic system as a new target for puta-
tive antidepressant drugs.
The dose-dependent antidepressant effect induced by PPADS in
the present work is in accordance with our previous published
paper (Pereira et al., 2013). Further, PPADS co-treatment with
FLX and RBX, in subeffective doses, induced a significant
antidepressant-like effect, thus suggesting that both serotonergic
and noradrenergic mechanisms might participate in PPADS-
induced antidepressant-like effects. When two drugs are combined
Table 1
5HT, NA and 5HIAA levels on PFC and HPC of PCPA and DSP4 treated animals. (a) DSP4 was infused i.c.v. 24 h before euthanasia. Two groups were obtained: VEH (n = 6) and DSP4
(n = 6). (b) PCPA (150 mg/kg) was administered once a day for 4 days. On the fourth day PCPA was administered 1 h before euthanasia. Serotonin, noradrenaline and serotonin
metabolite levels were analyzed on frontal cortex and hippocampus with HPCL method. All data are expressed as Mean ± SEM of ng/mg tissue, *p < 0.05 from control group;
**p < 0.01 from control group. Number of animals per group here is based in number of samples which HPCL MS determination was possible (in the graphic), although number of
animals euthanized is higher (VEH n = 6/DSP4 n = 6; VEH n = 5/PCPA n = 5).
Neurotransmitter levels
Vehicle DSP4 t-test p Vehicle PCPA t-test p
Frontal cortex
Noradrenaline 0.127 ± 0.018 (n = 6) 0.127 ± 0.010 (n = 6) t10 = 0.02 0.98 0.049 ± 0.004 (n = 4) 0.039 ± 0.003 (n = 5) t7 = 2.49 0.04*
5HT 0.260 ± 0.025 (n = 6) 0.314 ± 0.020 (n = 6) t10 = 1.67 0.12 0.087 ± 0.006 (n = 4) 0.077 ± 0.006 (n = 5) t7 = 1.10 0.31
5HIAA 0.099 ± 0.017 (n = 6) 0.121 ± 0.007 (n = 6) t10 = 1.18 0.27 0.035 ± 0.014 (n = 3) 0.023 ± 0.002 (n = 5) t6 = 1.10 0.31
Hippocampus
Noradrenaline 0.237 ± 0.028 (n = 5) 0.156 ± 0.017 (n = 5) t8 = 2.45 0.04* 0.080 ± 0.009 (n = 4) 0.082 ± 0.006 (n = 5) t7 = 0.16 0.88
5HT 0.324 ± 0.032 (n = 5) 0.192 ± 0.012 (n = 5) t8 = 3.88 0.004** 0.082 ± 0.012 (n = 4) 0.076 ± 0.006 (n = 5) t7 = 0.49 0.64
5HIAA 0.334 ± 0.048 (N = 5) 0.207 ± 0.017 (n = 5) t8 = 2.49 0.04* 0.066 ± 0.007 (n = 4) 0.048 ± 0.003 (n = 5) t7 = 2.65 0.03*
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other effects, reduce or block each other’s action (antagonism), or
facilitate each other’s action (synergistic or additive effects). There-
fore, the combination of subeffective doses of different drugs
allows the investigation of ‘‘agonistic” drug interactions amongst
them (Chou, 2006). Based on that, researchers have used this phar-
macological approach as a first step in identifying possible phar-
macological interactions that could guide to further
investigations on a given drug mechanism of action (Chou, 2006).
For instance, Harkin, et al. (2004) demonstrated that the combina-
tion of subeffective doses of nNOS inhibitor with subeffective doses
of fluoxetine, but not with desipramine, induced effect in the FST,
suggesting the participation of serotonergic, but not noradrenergic,
mechanisms in the evaluated antidepressant-like effects. This was
further confirmed in that study when PCPA pretreatment blocked
drug-induced antidepressant effect. Thus, a similar approach was
employed in the present study as an attempt to investigate sero-
tonin and noradrenaline involvement on PPADS effects in the
FST. Data obtained with depletion studies partially supported the
findings with subeffective doses, since both PCPA and DSP-4 atten-
uated PPADS-induced antidepressant-like effects in the FST.
Absence of per se effect of PCPA on immobility is in agreement
with animals and human research regarding monoamine hypothe-
sis of depression. In fact, our data are in agreement with other
papers that failed to find effects of PCPA on immobility in the
FST and other animal models (O’Leary et al., 2007; Page et al.,
1999). Accordingly, serotonin depletion does not precipitate
depressive symptoms in health individuals, but blocks the antide-
pressant effect of serotonergic drugs (Delgado, 2006; Moreno et al.,
2010). Similarly, PCPA treatment protocols and results have been
described by others where PCPA blocked antidepressant effects in
the FST (Harkin et al., 2003; O’Leary et al., 2007).
PCPA is considered a potent depletor of brain serotonin in mice,
rats and dogs (Koe and Weissman, 1966). It is well documented
that PCPA does not inhibit monoamine oxidase or 5HTP-
decarboxylase and it has no effect on monoamine oxidase or
5HTP decarboxylase activity of rat tissues in vivo, thus inducing
5-HT depletion by inhibiting the biosynthesis of this monoamine,
possibly by blocking tryptophan hydroxylation (Koe and
Weissman, 1966). Other studies have confirmed PCPA acts as a
serotonin synthesis inhibitor leading to decreased serotonin levels
in different brain regions, depending on dose and treatment sched-
ule (Datla and Curzon, 1996; Kornum et al., 2006).
Regarding DSP4 experiments, a decreased locomotor activity
was verified in both DSP4 + VEH and DSP4 + PPADS groups, which
might originate from DSP4 effect per se on locomotor activity. In
fact, it cannot be excluded that partial reversal of PPADS
antidepressive-like effect by DSP4 might be related to a non-
specific DSP4 effect on locomotion. However, that is unlikely, pro-vided DSP40s effect in decreasing locomotor activity did not pre-
vent its own antidepressant-like effect.
DSP-4 mechanism of action is less understood. However, it is
known it depletes noradrenaline content in dose-dependent fash-
ion, in different brain regions (Dailly et al., 2006) and rodent spe-
cies (Fornai et al., 1996). It is reported that after a single i.p.
injection of DSP-4, this neurotoxin is uptaken by noradrenergic
neurons (Ross and Renyl, 1976; Hallman and Jonsson, 1984), which
start to degenerate in the LC target structures (Fritschy and
Grzanna, 1989).
Taken together, drugs that inhibit monoamine synthesis or
release, such as PCPA and DSP-4 represent important tools that
can help characterizing the mechanisms underlying an
antidepressant-like effects of a new drug or reveal underlying vul-
nerability to stress (Cryan et al., 2002b; O’Leary et al., 2007).
In the present work, HPLC analysis of monoamine levels in brain
regions of animals treated with PCPA revealed decreased nora-
drenaline levels in the frontal cortex, while it decreased serotonin
main metabolite 5-hydroxyindoleacetic acid (5HIAA) levels in hip-
pocampus. Changes in brain catecholamines after PCPA systemic
administration, although subtle, were observed in the original
work of Koe and Weissman (1966). Indeed, catecholamine levels
can be slightly decreased after PCPA administration, especially in
high doses (Koe and Weissman, 1966; Datla and Curzon, 1996;
Kornum et al., 2006), as we observed in the present work. Tyrosine
hydroxylase was also slightly inhibited in vitro with PCPA infusion
and plasma tyrosine levels were slightly reduced after systemic
PCPA injection (Koe and Weissman, 1966). Curiously, 5HT levels
did not change in either frontal cortex or hippocampus, which is
in disagreement with other works (Shutoh et al., 2000; Fletcher
et al., 2001; Page et al., 1999). Differences in methodological anal-
ysis of serotonin content or in drug administration and brain dis-
section protocols might explain such contradictory results.
Besides, other structures involved with modulation of behavioral
consequences of stress such as hypothalamus, bed nucleus of the
stria terminalis, nucleus accumbens and amygdala could present
serotonin levels changes, but this possibility was not verified in
the present work. Although no change was observed on serotonin
levels after PCPA treatment, 5HIAA hippocampal levels were
decreased. Concentration of 5HIAA has been used to estimate the
activity of serotonergic neurons (Shannon et al., 1986). In fact, elec-
trical stimulation of the dorsal raphe nucleus increased 5HIAA
levels and 5HIAA/5-HT concentration ratio in the nucleus accum-
bens, amygdala, suprachiasmatic nucleus and dorsomedial nucleus
(Shannon et al., 1986). Therefore, PCPA treatment used in the pre-
sent work was able to induce changes in both noradrenaline and
serotonin neurotransmission in the brain. Based on that, PCPA
effects cannot be considered selective to serotonin neurotransmis-
sion and its effects on other monoamines should be taken into con-
24 C.R.A.F. Diniz et al. / Brain Research 1676 (2017) 19–27sideration when discussing PCPA-induced effects. In addition, even
that other have described that similar treatment with PCPA
blocked the effect of antidepressant drugs in the FST (Harkin
et al., 2003; O’Leary et al., 2007), we observed only partial rever-
sion of PPADS effects in the FST (Fig. 3). This indicates that PPDAS
effects might involve monoaminergic mechanisms, although the
specific participation of noradrenalin and/or serotonin in PPADS
effects is not clear.
DSP4 treatment also decreased not only noradrenaline levels,
but also serotonin (5HT) and 5HIAA levels, in the hippocampus.
In the frontal cortex, no change was observed on noradrenaline,
serotonin or 5HIAA. Although the main neurotoxic effect of DSP-
4 on noradrenergic neurotransmission (Fornai et al., 1996), other
works have described decreased serotonin levels in the cerebellum
and in the spinal cord (Jonsson et al., 1981), which is in agreement
with our results. It might also seem surprising that DSP-4
decreased neurotransmitter levels in a specific brain region,
instead of all over the brain. However, this has been described by
others that noradrenergic terminals originated in the locus coeru-
leus are more susceptible to DSP-4 depleting and neurotoxic effects
than those in ventral forebrain and hypothalamus, which are sup-
plied primarily by non-coerulean NE cells (Grzanna et al., 1989).
The mechanisms responsible for those differences are not clear,
but could rely on differences in the pharmacological properties of
NE axon terminals, such as neuronal density and transporter avail-
ability (Grzanna et al., 1989). Another reasonable explication is
that hippocampus is located close to the ventricular wall, then is
possible that i.c.v. drug infusion reached hippocampal region easier
than distant areas such as the frontal cortex.
Several reports describe noradrenaline levels are decreased in
the brain after systemic injections of DSP4, whereas microdialysis
studies indicate extracellular noradrenaline levels are actually
increased (for review see Ross and Stenfors, 2015). Other in vivo
microdialysis studies (Hughes and Stanford, 1998; Kask et al.,
1997) have shown that pretreatment with DSP-4 (40 mg/ kg) actu-
ally leads to an increase in the basal extracellular concentration of
norepinephrine, in rat frontal cortex, despite causing a 75% lesion
of cortical norepinephrine content. That increase is further poten-
tiated following challenge with the norepinephrine reuptake inhi-
bitor desipramine. Accordingly, augmented behavioral response
was seen in reboxetine treated groups after DSP-4 treatment
(Cryan et al., 2002b), although an underlying mechanism for that
effect remains to be elucidated. Therefore, increased extracellular
levels of noradrenaline in some particular brain regions, despite
decrements in other brain regions, might help explaining the
antidepressant-like effect induced by DSP4 treatment per se. In this
sense, DSP4 attenuating effect of PPADS could be the result of a
complex interplay between both drugs acting through different
brain regions in the CNS.
ATP is recognized as a neurotransmitter accessible to perisy-
naptic glia and neurons, in addition to being released from glial
and neuronal cells (Pascual et al., 2005; Araque et al., 2014;
Halassa and Haydon, 2010; Lalo et al., 2014; Kato et al., 2004;
Koizumi et al., 2005). This dual functional role of purinergic system
contributes to signal integration between glial cells and neuronal
synapses, as a tripartite synapse (Pascual et al., 2005). Besides,
ATP could evoke astrocyte calcium waves leading to the release
of other transmitters such as glutamate, GABA and glycine
(Guthrie et al., 1999). In fact, interaction between glutamatergic
and purinergic neurotransmission has been the most studied so
far, with ATP facilitating neuronal and astrocyte glutamate release
(Burnstock, 2002; Burnstock, 2011; Shen et al., 2005).
Glutamate, as well as NO, which arises from NMDAR activation,
can control serotonin availability (Kuhn and Arthur, 1997; Fossier
et al., 1999). Evidences indicate that ATP itself is also able to atten-
uate serotonin release in rat brain cortex via P2R activation (VonKügelgen et al., 1997). Conversely, serotonin is also able to modu-
late ATP levels in the brain (Koren-Schwartzer et al., 1994). In this
context, the add-on effect observed with concomitant PPADS and
FLX administration could derive from P2R blockade favoring sero-
tonergic availability. In addition, a previous work from our group
showed PPADS attenuated NO levels in the prefrontal cortex at
the same dose that induced antidepressant-like effects in the FST
(Pereira et al., 2013). In line with data of the present work,
antidepressant-like effect induced by nNOS inhibitors is also
dependent on brain serotonin levels (Harkin et al., 2003). In fact,
it is known nNOS inhibition can increase the release of 5-TH in
the brain (Karolewicz et al., 2001). Altogether, this evidence sug-
gests serotonergic mechanisms might be involved in PPADS-
induced antidepressant-like effects. However, pretreatment with
PCPA only partially reversed PPADS effect on FST, which suggests
that serotonin might be involved in PPADS mechanism, although
other neurotransmitters may also play an important role.
Regarding noradrenaline involvement on PPADS effects, it is
shown that activation of presynaptic P2R increase the release of
noradrenaline in the locus coeruleus (Tschopl et al., 1992), whereas
it decreases noradrenaline availability in the rat cortex (von
Kügelgen et al., 1994) and hippocampus (Koch et al., 1997). These
data reveal a complex role for ATP in regulating noradrenaline
levels in the brain. Our results showing that combination of sub-
effective doses of PPADS with RBX induced antidepressant-like
effect suggests the involvement of central noradrenergic mecha-
nisms in PPADS effects on FST. Moreover, the fact that DSP4 was
able to reduce PPADS effects, although without blocking it, gives
further support to that possibility.
Previous work by Iwata et al. (2016) proposes an alternative
mechanism for P2X7-antagonist induced antidepressant-like
effects. Their work showed immobilization stress increased gluta-
mate, ATP and inflammatory cytokines levels in hippocampus
microdialysates, which was blocked by systemic treatment with
P2X7 antagonist. Authors suggested that modulation of inflamma-
some complex after stress exposure would be involved in the
antidepressant-like effect induced by P2X7 blockade. In fact,
P2X7 receptors are also expressed in glia and they can trigger
inflammasome activation and depressive-like behaviors (Yue
et al., 2017). On the other hand, inhibition of inflammasome
response seems to be a common mechanism of different antide-
pressant drugs (Alcocer-Gómez et al., 2017). However, the activa-
tion of inflammasome by stress has been shown only after
chronic stress exposure (Yue et al., 2017; Iwata et al., 2016;
Kaufmann et al., 2017). Since we employed acute stress in mice,
it is unlikely this would have played an important role in our
experiments. It is, however, possible that blockade of glutamate
release from astrocytes by P2X blockade might have contributed
to the observed antidepressant effect. However, since neuronal
release of ATP is also evidenced (North, 2002) and P2R are
expressed either in glial or neuronal cell types (Burnstock, 2008),
it is not possible to presume which cell types might have con-
tributed to PPADS effects in the present work. Besides that, the
complex and close relationship between glial and neuronal cells
mediating purinergic signaling (tripartite synapse) makes cell
types discernment harder (Pascual et al., 2005). Nevertheless, it
is possible to speculate that different mechanisms and cell types
could be involved in acute and chronic effects on P2X7-mediated
signaling. Accordingly, the antidepressant-like effect of PPADS,
acquired after acute stress exposure, most probably would be pro-
vided by direct regulation of ATP activity on P2X7R present in neu-
rons. However, in chronic stress conditions, P2X7 blockade might
attenuate depressive-like behaviors by mixed effects, either by
blocking ATP/P2X7R binding in astrocytes and thus attenuating
neuroinflammatory responses or glutamate release, or by direct
regulation of neuronal firing rate. Therefore, blockade of P2X7
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ent mechanisms, depending on the model under investigation
(acute vs. chronic stress).
Finally, the results of the present study about serotonin and
noradrenalin involvement on PPADS effects should be considered
in the light of its limitations. For instance, a parsimonious interpre-
tation must be done regarding the add-on effect of subeffective
doses of PPADS plus RBX or FLX, since the combination of sub-
thresholding doses does not necessarily imply a convincing inter-
action or synergistic effect among two drugs with different mech-
anism of action (Foucquier and Guedj, 2015). In fact, to assert a
reliable synergistic or interaction of mechanism of action between
the drugs, an isobologram analysis is required (Tallarida, 2006).
Moreover, although PPADS + VEH group was not different from
PPADS + PCPA or PPADS + DSP-4, significantly differed from VEH
+ VEH control group, indicating only partial reversion of PPADS
effects without complete blockade. In addition, the complex effect
of PCPA and DSP-4 on monoamine levels observed herein is an
important limitation of the present study that should also be taken
into consideration for the interpretation of the results. Neverthe-
less, in conclusion, the present study adds further evidence to pre-
vious studies, suggesting blockade of P2R induces antidepressant-
like effects. Moreover, it suggests the involvement of serotonin
and/or noradrenaline in such effects, although further studies
regarding purinergic/monoaminergic interplay are still necessary
to better understand the pharmacological mechanisms involved
on that.4. Materials and methods
4.1. Animals
A total of 352 male Swiss mice weighing 30–40 g (6–7 weeks)
were used. Animals were housed in groups of 6–8 per cage
(570 cm2) in a temperature controlled room (24 ± 1 C) under stan-
dard laboratory conditions with free access to food and water and a
12 h light/12 h dark cycle (light on at 6:30 a.m.). Animals were ran-
domly assigned for experimental groups described bellow and pro-
cedures were performed in conformity with the Brazilian Council
for the Control of Animals under Experiment (CONCEA), which
comply with international laws and politics. The local Ethical Com-
mittee approved experimental protocol (146/2009), and all efforts
to minimize animal suffering were made.4.2. Drugs
Pyridoxalphosphate-6-azophenyl-20,40-disulfonic acid tetra-
sodium salt (PPADS, a non-selective P2R antagonist, Tocris, USA,
#0625), fluoxetine hydrochloride (FLX, selective serotonin reup-
take inhibitor, Prati-Donaduzzi, Brazil, #713198), reboxetine
mesylate (RBX, selective noradrenaline reuptake inhibitor, Ascent
Scientific, USA, #157), p-Chlorophenylalanine (PCPA, tryptophan
hydroxylase inhibitor, Sigma-Aldrich, EUA, #C6506), N-(2-chloroe
thyl)-N-ethyl-2-bromobenzylamine hydrochloride (DSP4, nora-
drenergic neurotoxin, TOCRIS, USA, #2958) were used. All drugs
were prepared administered intraperitoneally (i.p.) at 10 mL/kg,
except for DSP4, which was infused intracerobroventricularly in
1ml volume. DSP4 and FLX were dissolved in Tween 80 2% in sterile
saline, while all other drugs were dissolved in sterile isotonic sal-
ine. 2,2,2-tribromoethanol (Aldrich Chemical, USA, #T48402) was
used for stereotaxic surgery and chloral hydrate (Sigma Aldrich,
USA, #V000554) was used to euthanize the animals for tissue
collection.4.3. Forced swimming test (FST)
Animals were individually submitted to 6 min of forced swim-
ming in glass cylinders (height 25 cm, diameter 17 cm) containing
10 cm of water at 24–26 C. The test was videotaped and immobil-
ity time (characterized by limb movements necessary for floating)
was measured during last 4 min of the test by a trained observer
blinded to the treatment condition. All behavioral procedures are
in accordance to established protocols (Porsolt et al., 1977). The
water was changed after each trial (Abel and Bilitzke, 1990).
4.4. Open field test (OFT)
The OFT was used to measure locomotor activity of animals
according to Zanelati et al. (2010). Mice were placed individually
in a circular open field arena (40 cm in diameter and 50 cm high
Plexiglas wall) for 6 min. The exploratory activity was videotaped
and number of crossings between quadrants was measured during
last 4 min by an observer blinded to the treatment condition. After
each trial, arena was cleaned with 70% alcohol solution.
4.5. Sample collection and High-performance liquid chromatography
(HPLC)
Animals were deeply anesthetized with chloral hydrate 5%
(0.75 g/kg, ip) for brain removal. The frontal cortex and hippocam-
pus were dissected on ice and processed for determination of sero-
tonin, noradrenaline and serotonin metabolite (5HIAA) levels as
described by Patel et al. (2005). Samples were homogenized in
0.1 M perchloric acid, afterward centrifuged at 13000 rpm for
10 min at 4 C. Supernatant was automatically injected into the
chromatographic system to quantify neurotransmitters and
metabolites by electrochemical detection in high-performance liq-
uid chromatography (HPLC). The chromatograph (Waters Alli-
ance) consisted of a stripping column Symmetry C18, 5 lm
(150  4.6 mm) and mobile phase flow 1ml/min with the following
composition: buffer (88.2%; citric acid 0.05 M, sodium octyl sulfate
250 mg/L, EDTA 0.1 mM, potassium chloride 2 mM and pH
adjusted to 3.2 with NaOH), methanol (9.3%) and acetonitrile
(2.5%). Mobile phase was vacuum filtered and degassed ultrasoni-
cally. Calibration curve was constructed with standard solutions of
2.5, 5, 10, 25, 50, 100 and 200 ng/ml of norepinephrine, serotonin
and 5HIAA, which were injected into the chromatograph in tripli-
cate. Detection and limit of quantification were 0.64 and 2.13 ng/
ml for serotonin; 1.72 and 5.73 ng/ml for 5HIAA and 0.87 and
2.88 ng/ml for noradrenaline. Samples with concentrations found
below limit of quantitation were discarded. Finally, concentrations
of the substances were corrected by the mass of dissected tissue
samples being expressed in ng of substance per mg of tissue.
4.6. Stereotaxic surgery and intracerebral administration
Mice were anesthetized with 2,2,2-tribromoethanol 2.5%
(10 ml/kg intraperitoneal, ip) and fixed in a stereotaxic frame.
One Stainless steel guide cannula (0.7 mm OD) was implanted
and aimed at the lateral ventricle (coordinates: anteroposte-
rior = 0.3 mm from lambda, lateral = 1.2 mm, dorsoven-
tral = 2.5 mm) according to the Paxinos and Franklin’s atlas
(Paxinos and Franklin, 1997). The cannula tip was placed 1mm
above site of injection and attached to the skull bone with stainless
steel screws and acrylic cement. A stylet inside guide cannula pre-
vented obstruction.
Five to seven days after surgery intra-cerebroventricular (i.c.v)
injections were performed with a thin dental needle (0.3 mm
OD). A volume of 1 ll per animal was injected in 30 s using a
micro-syringe (Hamilton) controlled by an infusion pump (Insight
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was interposed between upper end of the dental needle and the
micro-syringe. Movement of an air bubble inside the polyethylene
catheter confirmed drug flow.
4.7. Histology
After the behavioral tests, mice were deeply anesthetized with
chloral hydrate 5% (0.75 g/kg, ip) and a dental needle was inserted
through the guide cannulae to infuse 0.5 ml of methylene blue.
Immediately after, animals were euthanized for brain removal.
The injection sites were confirmed as correct, on fresh brain, after
the dye has spread to the whole brain through cerebroventricular
way. Results from injections outside target area were discarded
from statistical analysis.
4.8. Experimental protocols
4.8.1. Dose-response curves for FLX, RBX and PPADS treatment on mice
FST and OFT
Experimentally naïve mice received a single ip injection of
PPADS (3, 6.25, 12.5 mg/kg), FLX (10, 20, 30 mg/kg), RBX (2.5, 5,
10 mg/kg) or vehicle and, 30 min later, submitted to FST. An inde-
pendent cohort of animals received single ip injections of effective
doses of PPADS (6.25 mg/kg), FLX (20 mg/kg), RBX (5 mg/kg) or
vehicle and submitted to OFT 30 min later.
4.8.2. Add on effects of PPADS sub-effective dose to FLX or RBX sub-
effective doses on FST and OFT
Independent group of animals received a first injection of saline,
FLX 10 mg/kg or RBX 2.5 mg/kg, immediately followed by a second
injection of saline or PPADS 3 mg/kg. Thus, six groups were
obtained: VEH+VEH, FLX + VEH, RBX + VEH, PPADS + VEH, FLX
+ PPADS, RBX + PPADS. Animals were submitted to FST 30 min
after last administration. An independent cohort of animals
received ip injections of FLX (10 mg/kg), RBX (2.5 mg/kg) or vehi-
cle, immediately followed by PPADS (3 mg/kg), and submitted to
OFT 30 min after last administration.
4.8.3. Effect of 5-HT depletion on PPADS effects on FST and OFT
behavior
Experimentally naïve mice received daily ip injections of PCPA
(150 mg/kg for 4 days) or VEH. On the fourth day, the last PCPA
dose or VEH infusion were done 30 min before the second injection
with VEH or PPADS (6.25 mg/kg). Animals were submitted to FST
30 min after second injection. PCPA dose and infusion schedule
were chosen based on a previous work (Haring et al., 2013). An
independent cohort of animals was submitted to the same treat-
ment regimen described above and submitted to the OFT 30 min
after second injection.
4.8.4. Effect of NA depletion on PPADS effects on FST and OFT
Experimentally naïve mice, with surgically implanted cannula,
received i.c.v. infusion of VEH or DSP4 (20 mg) followed, 24 h later,
by ip injections of PPADS (6.25 mg/kg) or VEH, and submitted to
FST 30 min after ip administrations. DSP4 dose was chosen based
on a previous work (Choi et al., 2003). An independent cohort of
animals was submitted to the same treatment regimen described
above and submitted to the OFT 30 min after last injection.
4.8.5. 5HT, NA and 5HIAA levels on PFC and HPC of PCPA and DSP4
treated animals
Experimentally naïve mice received daily ip injections of PCPA
(150 mg/kg for 4 days) or VEH and euthanized 30min after last
administration. An independent cohort of mice, received i.c.v infu-
sion of DSP4 (20 ug) or VEH 24 h before euthanasia. The levels of5HT, NA and 5HIAA levels were analyzed on PFC and HPC through
HPCL as described.4.9. Statistical analysis
Data from experiment 1 were analyzed in column comparison
by one-way ANOVA, followed by Dunnett’s post hoc test. Experi-
ments 2 (FST), 3 and 4 were firstly analyzed by two-way ANOVA
and injections was described as factors (except for OFT concerning
experiment 2 that only One-way ANOVA was used). Thereafter,
consecutive any significant difference, a column comparison was
performed followed by Newman-Keuls’s Multiple comparisons
post hoc test. Regarding column comparison, non-parametric
Dunn’s post hoc test was used when appropriate. Data from exper-
iment 5 was analyzed by Student’s t test. Statistical differences
were considered significant when p < 0.05. SPSS 20.0 software for
windows (IBM SPSS statistics, Chicago, IL, USA) was used to the
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